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Abstract
Background: The increasing emphasis on patient-reported outcomes in health care decision making has prompted
greater rigor in the evidence to support the instruments used. Acceptability and content validity are important
properties of any measure to ensure it assesses the relevant aspects of the target concept. The purpose of this
study was to evaluate the acceptability and content validity of the EQ-5D 5-Level (EQ-5D-5L) to assess the impact of
asthma on patients’ lives.
Methods: Qualitative interviews were conducted with 40 adults with asthma in the United Kingdom. The first 25
interviews used cognitive-debriefing methods to assess the relevance and acceptability of the EQ-5D-5L and two
asthma-specific measures for comparison: an asthma-specific, preference-based measure (the Asthma Quality of Life
Utility Index–5 Dimensions) and an Asthma Symptom Diary. The final 15 interviews combined concept elicitation to
identify patient-perceived asthma impact, and cognitive debriefing to assess relevance and acceptability of the
EQ-5D-5L and the Asthma Symptom Diary. Cognitive-debriefing feedback on the content of the measures was
collated and summarized descriptively. The concept-elicitation data were analyzed thematically.
Results: Participants were aged 20 to 57 years and 62.5% were female. Although some participants expressed positive
opinions on aspects of the EQ-5D-5L, only the usual activities dimension was consistently considered relevant to
participants’ asthma experiences. The mobility and self-care dimensions prompted strong negative reactions from
some participants. Variations in interpretation of the mobility dimension and difficulties with multiple concepts in the
pain/discomfort and anxiety/depression dimensions also were noted. Concepts reported by participants as missing
included environmental triggers, asthma symptoms, emotions, and sleep. The EQ-5D-5L was the least preferred
measure to describe the impact of asthma on participants’ lives. Participants reported shortness of breath and impact
on activities as especially salient issues.
Conclusions: The content of the EQ-5D-5L was poorly aligned with the patient-perceived impact of asthma, and the
measure failed to meet basic standards for acceptability and content validity as a measure to assess the impact of
asthma from the patient perspective. The shortcomings identified raise concerns regarding the appropriateness of the
EQ-5D in asthma and further evaluation is warranted.
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Background
In the context of health economic evaluation, preference
-based measures (PBMs) are used to represent the
quality-of-life impact component of the quality-adjusted
life-year (QALY) in cost-utility analyses [1]. The EQ-5D
[2] is a patient-reported outcome (PRO) measure and is
one of the most widely used PBMs for cost-utility ana-
lysis [3, 4]. The instrument is the measure of choice for
many health technology assessment bodies, including
the National Institute of Health and Care Excellence
(NICE) in England [5], and is increasingly being used in
the United States [6]. Although the EQ-5D is widely
used, shortcomings have been noted in relation to its
content coverage and its sensitivity and responsiveness
in certain populations, particularly for patients with
“mild” conditions [7, 8]. While studies have indicated
that the increase in the number of response levels in the
descriptive system of the 5-level EQ-5D (EQ-5D-5L) [7]
has improved measurement precision [9] (although the
currently unresolved discrepancies between the 3-level
EQ-5D (EQ-5D-3L) and EQ-5D-5L value sets in the
United Kingdom/England are noted [10, 11]), the
EQ-5D-5L will not overcome any issues that are associ-
ated with irrelevant or missing content.
Concerns about the relevance and sensitivity of generic
PBMs in some conditions has prompted the develop-
ment of a number of condition-specific PBMs, including
the Asthma Quality of Life Utility Index–5 Dimensions
(AQL-5D) in asthma [12, 13], the EORTC-8D in cancer
[14], and the NEWQOL-6D in epilepsy [15]. However,
evidence for the increased sensitivity of such measures
compared to generic PBMs has varied; for example, Lor-
gelly et al. [16] found similar levels of sensitivity in the
EORTC-8D and the EQ-5D-3L in cancer, whereas
McTaggart-Cowan et al. [17] demonstrated that the
AQL-5D was better able to distinguish between differing
levels of asthma control compared to three different generic
instruments (Health Utilities Index-Mark 3, EQ-5D-3L,
and the SF-6D). In relation to the NEWQOL-6D in
epilepsy, Mulhern et al. [18] reported that, although
the condition-specific PBM was generally more sensi-
tive than the EQ-5D-3L, this did not result in large
differences in utility.
Even if greater sensitivity can be demonstrated, the im-
plementation of condition-specific PBMs for cost-utility
analysis has been limited by the lack of ability to com-
pare utility values across diseases and the potential of
some condition-specific measures (although not all) to
miss the impact of side effects and comorbidities [19].
Moreover, while it is recognized that generic PBMs some-
times may miss or underestimate important health-related
quality of life (HRQOL) changes, from the perspective of
economic evaluation, the focus is whether the measure “is
sensitive enough” [16]. Given the lack of definitive criteria
for sufficient sensitivity, this question is not easily an-
swered. Furthermore, there is no consensus on the most
appropriate way to assess this property for PBMs; Brazier
and Deverill [20] suggested that traditional psychometric
methods for testing construct validity and responsiveness
often were not applicable to PBMs.
The increasing emphasis on PROs in health care deci-
sion making has prompted greater rigor in the evidence
to support the instruments used [21, 22]. Any PRO in-
strument must be shown to be fit for purpose, given the
intended context of use, and there are numerous guide-
lines outlining measurement quality standards (see for
example, [23, 24]).
While there is debate on the applicability of some psy-
chometric criteria to PBMs [20], content validity is a key
requirement for any PRO measure, including PBMs, to
ensure the instrument assesses the relevant and import-
ant aspects of the target concept of measurement [20,
25]. In the context of PBMs used to calculate QALYs,
the target concept is HRQOL [5]. Although a consensus
definition of HRQOL does not exist [26, 27], it is typic-
ally considered to be a multidimensional concept that
encompasses domains relating to physical, mental,
emotional, and social functioning [28]. Although
NICE prioritizes generic instruments (and thus gen-
eric HRQOL) in its reference case, it recognizes the
importance of understanding the patient perspective
on the relevance of such instruments to the specific
disease under consideration [5].
The purpose of this study was to explore the accept-
ability and content validity of the EQ-5D-5L from the
perspective of patients with asthma. Asthma is an epi-
sodic condition, characterized by periods of disease con-
trol that are punctuated by debilitating, and potentially
life-threatening exacerbations of varying durations.
Questions have been raised about the ability of the
EQ-5D to reflect the full impact of episodic conditions
due its recall of “today” [29] and whether the measure is
able to capture the impact of exacerbations in between
attacks (e.g., fear of future attacks) [30]. Although stud-
ies have evaluated the content validity of the EQ-5D
(see, for example, Matza et al. [31] and van Leeuwen et
al. [32]), we are not aware of any studies that have evalu-
ated this property directly with patients in asthma. Thus,
this study sought to assess the acceptability and content
validity of the EQ-5D-5L as a measure to assess the im-
pact of asthma from the patients’ perspective.
Methods
Study design
A total of 40 qualitative interviews were conducted with
adults with asthma. In the first 25 interviews (interview
sample 1), cognitive debriefing was used to elicit feed-
back on the content of the EQ-5D-5L, as well as two
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asthma-specific measures for comparison purposes: the
Asthma Symptom Diary (ASD) [33, 34], and the
AQL-5D [12, 13]. Cognitive debriefing through qualita-
tive patient interviews is used to establish the acceptabil-
ity and content validity of PRO instruments [25, 35] by
evaluating how patients interpret questionnaire items
and confirming appropriateness, comprehensiveness,
and understandability [25, 36]. The AQL-5D was se-
lected as it is a frequently used as a condition-specific
PBM in asthma. The ASD also was included to evaluate
the acceptability to patients of a symptom-related impact
measure; it is noted that, although criticized in the con-
text of QALYs by some authors [13], symptom-based
utility measures in asthma have been developed [37].
In the final 15 interviews (interview sample 2), the op-
portunity was taken to identify the concepts of relevance
and importance to patients prior to cognitive debriefing
of the instruments. Employing focused, open-ended
questions relating to a specific topic of interest, concept
elicitation is commonly used to elicit patients’ spontan-
eous self-reports of their experiences with their condi-
tion [38] and is a key method to establish content
validity of PRO instruments [36]. To avoid overburden-
ing participants, cognitive debriefing of the AQL-5D was
not included in these 15 interviews.
The study was reviewed and granted approval from
one of RTI International’s institutional review boards.
Study sample
The study sample was a convenience sample of 40 adults
with asthma recruited from the northwest region of the
United Kingdom through a medical fieldwork agency.
Participants were included if they were aged 18 years or
older, had a self-reported physician-diagnosis of asthma,
used at least one controller asthma medication, were
able to read and complete an English-language paper
questionnaire, and were able to provide written in-
formed consent. Participants were excluded if they were
aged over 50 years and had a history of smoking for
15 years or longer, or had a significant comorbidity. To
minimize potential sampling bias arising from the con-
venience sampling approach, participants were recruited
to represent a range of asthma severity, asthma control,
and exacerbation history.
There are no definitive guidelines for determining
sample sizes for qualitative research. In the context of
cognitive-debriefing interviews, where the aim is to iden-
tify potential problems with a measure, sample sizes of
between 5 and 15 are typical [39], although samples as
high as 30 also have been recommended [40]. For con-
cept elicitation, the emphasis is often on achieving con-
cept saturation, that is, the point at which no new
relevant information is elicited from subsequent inter-
views [36]. It has been suggested that for studies in
which the aim is to understand perceptions and experi-
ences in a relatively homogeneous group, as few as 12
interviews should be sufficient to reach saturation [41].
Thus, it was anticipated that the sample sizes of 40 for
cognitive debriefing and 15 for concept elicitation would
be adequate to achieve the objectives of this study.
Study instruments
The EQ-5D [2] is a generic measure that was developed to
assess health status across diseases on a common scale.
The EQ-5D-5L [7] is a descriptive system comprising five
dimensions (mobility, self-care, usual activities, pain/dis-
comfort, and anxiety/depression), each with five response
levels, ranging from no problems (1) to extreme problems
(5). The dimensions for the EQ-5D were identified and re-
fined through a detailed review of other available generic
health measures and further empirical testing [42].
The ASD [33, 34] is a diary instrument designed to as-
sess asthma symptoms and symptom-related impacts. The
diary is intended to be completed by patients twice daily
(morning and evening). The morning diary assesses the
nighttime severity of four symptoms (wheezing, shortness
of breath, cough, and chest tightness), as well as the num-
ber of nighttime awakenings. The evening diary assesses
the same four symptoms and the extent to which activities
were limited during the day. The content of the ASD was
developed and refined based on clinical input and qualita-
tive interviews with patients with asthma.
The AQL-5D [12, 13] is a PBM derived from the
Asthma Quality of Life Questionnaire (AQLQ). The
AQLQ [43] is a 32-item asthma-specific HRQOL measure
comprising four domains: activity limitations, emotional
function, exposure to environmental stimuli, and symp-
toms. The content of the AQLQ was developed and re-
fined based on a literature review, existing HRQOL
measures, discussions with physicians, and interviews and
a survey with patients with asthma. The AQL-5D has five
dimensions that were identified through principal compo-
nents analysis of the AQLQ items: general symptoms
(shortness of breath), sleep symptoms (interference with
getting a good night’s sleep), activity (limitation with all
activities done), emotion (concerns about having asthma),
and environmental stimuli (experience of symptoms as a
result of air pollution and weather).
Participants also completed questions on sociode-
mographics and asthma status. To assess asthma con-
trol, participants completed four questions outlined
by the Global Initiative for Asthma [44], as well as
the 6-item Asthma Control Questionnaire (ACQ-6)
[45]. Scores on the ACQ-6 range from 0 to 6; higher
scores reflect poorer asthma control. A score of 1.0
on the Asthma Control Questionnaire has been re-
ported as the cross-over between well-controlled and
not well-controlled asthma [46].
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Interview procedures
The interviews were conducted by experienced inter-
viewers and were facilitated by an interview guide. In-
formed consent was obtained prior to initiating the
interview and participants then completed the back-
ground and asthma control questions.
Interview sample 1 (n = 25) completed the EQ-5D-5L,
the ASD, and the full AQLQ. The ordering of the instru-
ments was varied to minimize bias. After completion of
all three instruments, participants were asked debriefing
questions to explore the acceptability, relevance, and
comprehensiveness (i.e., whether any issues of import-
ance were missing) of each instrument. For the AQLQ,
participants were asked to consider only the five
AQL-5D items during the debriefing. Participants rated
each instrument on a scale from 1 (not relevant at all) to
10 (extremely relevant) in terms of its relevance to de-
scribe the effect that asthma has on their lives. Finally,
participants were asked to select which instrument and
which individual items (with no limit on how many
items were selected) best described the effect that
asthma has on their lives.
Participants in interview sample 2 (n = 15) were first
asked about their experiences with asthma (including
symptoms and asthma attacks) and the impact of asthma
on daily life. Participants then completed the EQ-5D-5L
and the ASD, and were asked debriefing questions and
selected which instrument and which individual items best
described the effect that asthma has on their lives. The
ordering of instruments was alternated to minimize bias.
All interviews were audio recorded and detailed field
notes were taken. The audio recordings from the second
set of 15 interviews also were transcribed verbatim by a
medical transcriptionist independent to the research
team, to facilitate analysis of the concept-elicitation data.
Analysis
Participants’ feedback on the EQ-5D-5L, the AQL-5D, and
the ASD was collated and summarized using the interview
field notes or transcript data as available and supplemented
by the audio recordings, if needed. The concept-elicitation
transcript data from interview sample 2 were analyzed the-
matically using Atlas.ti 7 coding software (Atlas.ti; Berlin,
Germany). An initial coding frame was applied iteratively
to the transcript data and was updated as themes were re-
fined and new codes were developed. The analysis was con-
ducted by two researchers: one researcher undertook the
primary summarization or coding, and the second re-
searcher read the field notes and/or transcripts and
reviewed the summaries and applied codes. Any discrepan-
cies were resolved by the two researchers.
The output from the qualitative analysis was a descrip-
tive summary of participants’ feedback on the question-
naires and of the issues discussed in relation to the impact
of asthma. Concept saturation in the concept-elicitation
data was assessed by the emergence of new analysis codes
across successive sets of three interview transcripts [36].
Participants’ ratings of the relevance of each instru-
ment were summarized by the mean rating. Participants’
selections of the most relevant instrument and individual
items to describe the effect that asthma has on their
lives were summarized by frequency counts.
Results
Sample characteristics
The 40 participants ranged in age from 20 to 57 years,
and 62.5% were female (Table 1). Although most partici-
pants (92.5%) reported their asthma to be either mild or
moderate at the time of the interview, 85.0% were using
two or more controller medications, 57.5% had uncon-
trolled asthma, and the mean ACQ-6 score (1.7) indi-
cated not well-controlled asthma (Table 2).
Evaluation of the EQ-5D-5L
Participants in both samples had diverse opinions on the
relevance of the EQ-5D-5L. Although some participants
described it as measuring the issues impacted by asthma,
other participants considered it to be too general and
stated that some questions were not relevant to their ex-
periences of asthma. A number of participants indicated
that some of their responses would be unlikely to change
even when their asthma was at its most severe.
Individual participants found some of the questions,
particularly mobility and self-care, to be offensive. Such
participants spoke with indignation about being asked
these questions and dismissed them as being related to
conditions that were more physically debilitating, such
as arthritis:
“Some of them are almost a bit insulting…They
remind me of the questions we had when Mum was
going in a home and we were getting a statement to
assess and…you know. When I read those, it was like,
‘What? No!’ Disgrace.” (37-year-old female)
Mobility
Many participants (n = 17) did not consider that the
mobility dimension of the EQ-5D-5L related to their
experiences with asthma:
“Mobility isn’t relevant because I don’t see that it
does—well, it doesn’t affect my personal experience of
asthma because I’ve never had a problem with
mobility over it” (41-year-old male)
The level of functional impairment reflected in the di-
mension was reported as being relevant only during
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periods of severe illness or during an asthma attack. Par-
ticipants differed in their interpretation of the dimension
as including movements such as climbing stairs or walk-
ing uphill. Such differing interpretations could affect
participants’ responses; for example, one participant an-
swered ‘slight problems’ to the question, but when
probed, she stated that she had severe problems walking
up an incline.
Self-care
Self-care was not a relevant issue for a majority of par-
ticipants (n = 29), either in living with asthma day to day
or during an attack. Individual participants remarked
that self-care could possibly become an issue if they
were to ever become very ill.
“… personally from my asthma experience I find the
washing and dressing myself question incredibly
strange…Because I have never ever struggled to wash
or dress myself.” (20-year-old female)
Usual activities
The usual activities item was considered the most im-
portant of the five dimensions in the EQ-5D-5L. For
nearly all participants (n = 37), this dimension was a
relevant and central issue in their asthma:
“I think we’re talking here about activities of leisure and
family. I would say I have slight problems for the reasons
I’ve talked about really, energy levels and fitness, which
are affected by the asthma.” (41-year-old male)
“Yes, the ‘usual activities’ is relevant all the time
because that is the rollercoaster thing, isn’t it?” (30-
year-old female)
Pain or discomfort
Individual participants described asthma as painful and
thus welcomed the inclusion of the pain or discomfort
item in the EQ-5D-5L:
“It’s [asthma’s] really painful, and it just doesn’t seem to
be one of the things that is ever factored into it, so it’s
actually quite nice to see that there” (33-year-old female).
However, for most participants (n = 19), discomfort
was a more relevant concept than pain; and the combin-
ation of pain and discomfort in a single question had
implications for how participants responded. For ex-
ample, some participants who experienced discomfort in
relation to asthma rated their level of ‘pain or discom-
fort’ as less severe because they did not have pain. In
contrast, other participants answered only in relation to
discomfort because pain was irrelevant.
Table 1 Demographic Characteristics of the Interview Sample
Characteristic Interview Sample Total Sample
(N = 40)Sample 1 (n = 25) Sample 2 (n = 15)
Age (years)
n 25 15 40
Mean (SD) 38.7 (11.1) 36.5 (10.1) 37.9 (10.7)
Median (Q1, Q3) 37 (32.0, 45.0) 34 (31.0, 40.0) 37 (31.3, 45.0)
Range 21–57 20–55 20–57
Sex, n (%)
Male 10 (40.0) 5 (33.3) 15 (37.5)
Female 15 (60.0) 10 (66.7) 25 (62.5)
Relationships status, n (%)
Married or living as married 17 (68.0) 8 (53.3) 25 (62.5)
Divorced 1 (4.0) 1 (6.7) 2 (5.0)
Single 7 (28.0) 6 (40.0) 13 (32.5)
Employment status, n (%)
Working full time 13 (52.0) 8 (53.3) 21 (52.5)
Working part time 9 (36.0) 4 (26.7) 13 (32.5)
Retired 1 (4.0) 0 (0.0) 1 (2.5)
Student 1 (4.0) 2 (13.3) 3 (7.5)
Other 1 (4.0) 1 (6.7) 2 (5.0)
Q quartile, SD standard deviation
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“… they [pain and discomfort] are two different
words. I don’t think they should be allowed to be
joined together...I have never described that [asthma]
as painful. Discomfort, a little uncomfortable
sometimes, but never painful. It is not the word for an
asthma attack. I don’t think I have experienced it
anyway...with the pain there I would be tempted just
to tick the first one.” (26-year-old male)
Anxiety or depression
Although neither anxiety nor depression was particularly
relevant for many (n = 20) participants, anxiety generally
was considered to be the more relevant issue. Four
participants suggested that feelings such as concern,
frustration, or embarrassment were more suitable ex-
pressions of the psychological impact of asthma. In
addition, anxiety and depression were considered separ-
ate issues and their combination in a single item was
problematic. The implication of clinical depression pro-
voked strong reactions from individual participants:
“I just don’t like it being linked to the depression bit
though, so I would say that I’m anxious about it; but
when they put depression next to it as well, I’m not
depressed so I’d say it’s two separate questions…I just
don’t like those two; they’re really not nice phrases.”
(30-year-old female).
Table 2 Asthma Status of the Interview Sample
Characteristic Interview Sample Total Sample
(N = 40)Sample 1 (n = 25) Sample 2 (n = 15)
Duration of asthma diagnosis (years)
n 24 15 39
Mean (SD) 24.3 (12.4) 22.2 (10.4) 23.5 (11.6)
Median (Q1, Q3) 25.5 (13.0, 32.0) 20.0 (15.0, 30.5) 25.0 (13.5, 31.0)
Range 3–57 2.5–40 2.5–57
Self-reported severity of asthma, n (%)
Mild 8 (32.0) 3 (20.0) 11 (27.5)
Moderate 15 (60.0) 11 (73.3) 26 (65.0)
Severe 2 (8.0) 0 (0.0) 2 (5.0)
Very severe 0 (0.0) 1 (6.7) 1 (2.5)
GINA asthma control,a n (%)
Well controlled 1 (4.0) 1 (6.7) 2 (5.0)
Partly controlled 10 (40.0) 5 (33.3) 15 (37.5)
Uncontrolled 14 (56.0) 9 (60.0) 23 (57.5)
ACQ-6 score
n 25 15 40
Mean (SD) 1.6 (0.9) 1.9 (0.7) 1.7 (0.8)
Median (Q1, Q3) 1.7 (0.8, 2.0) 1.8 (1.6, 2.3) 1.8 (1.2, 2.3)
Range 0.3–3.7 0.7–3.3 0.3–3.7
Number of controller medications, n (%)
1 controller 5 (20.0) 1 (6.7) 6 (15.0)
2 controllers 18 (72.0) 10 (66.7) 28 (70.0)
3 controllers 2 (8.0) 4 (26.7) 6 (15.0)
Number of attacks in last 2 years, n (%)
0 9 (36.0) 1 (6.7) 10 (25.0)
1 5 (20.0) 5 (33.3) 10 (25.0)
2 6 (24.0) 7 (46.7) 13 (32.5)
3 or more 5 (20.0) 2 (13.3) 7 (17.5)
ACQ-6 6-item Asthma Control Questionnaire, GINA Global Initiative for Asthma, Q quartile, SD standard deviation
aGINA asthma control was based on participants’ responses to four questions on activity limitations, daytime symptoms, night awakening, and medication use:
well controlled = “no” responses to all four questions; partly controlled = “yes” responses to one or two questions; and uncontrolled = “yes” responses to three or
four questions [44]
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Evaluation of the EQ-5D-5L compared with the ASD and
the AQL-5D
In interview sample 1, the 1-to-10 rating for relevance
was highest (most relevant) for the ASD (mean: 8.5),
followed by the AQL-5D (mean: 7.5) and the EQ-5D-5L
(mean: 5.6). In the head-to-head comparison, more par-
ticipants selected the AQL-5D (n = 12) as the best in-
strument to describe the effects of asthma on their lives,
compared with the ASD (n = 8) or the EQ-5D-5L (n = 2).
The remaining three participants were undecided be-
tween the ASD and AQL-5D. In a similar head-to-head
comparison of the EQ-5D-5L and the ASD in interview
sample 2, the majority (n = 10) preferred the ASD, four
participants preferred the EQ-5D-5L, and one partici-
pant was undecided.
Across both sets of interviews, the reason given for
preferring the EQ-5D-5L often related to it assessing im-
pact, rather than just the cause of the impact (i.e.,
symptoms):
“Well because it’s [EQ-5D-5L’s] not just traditional
symptoms. I think the other questionnaire is about
symptoms. It’s like, can you breathe? Are you
coughing a lot? Are you waking up? Can you do
stuff? But this one’s, it’s almost like the next level
to that. It’s almost like the impact it has on your
life rather than the impact it has on your body.”
(33-year-old female)
However, many (n = 15) of the participants who pre-
ferred either the AQL-5D or the ASD commented that
the EQ-5D-5L dimensions lacked relevance to the im-
pact of asthma:
“… these [EQ-5D-5L questions] are so outside my
normal sphere of experience of asthma that I can’t
really relate to them too much.” (34-year-old male)
In interview sample 1, the individual items chosen most
frequently to best describe the impact of asthma were
the symptom and night awakening items from the ASD
and the weather and air pollution, sleep, and activities
items from the AQL-5D (Fig. 1). The EQ-5D-5L self-
care item was selected by only two participants, and the
anxiety/depression item was not chosen at all.
In interview sample 2, the questions selected the
most often were the symptom (except cough) and
night awakening items of the ASD and the usual
activities and pain/discomfort dimensions of the
EQ-5D-5L (Fig. 2). Once again, the mobility and
self-care items of the EQ-5D-5L were selected by
relatively few participants.
Across both interview samples, the issues identified as
being missing from the instruments included environ-
mental triggers, asthma symptoms, emotions (other than
anxiety or depression), and sleep for the EQ-5D-5L; en-
vironmental triggers, pain and fatigue, emotions, and
Fig. 1 Selection of Best Questions (Interview Sample 1; n = 25). AP air pollution; AQL-5D Asthma Quality of Life Utility Index–5 Dimensions; ASD
Asthma Symptom Diary; EQ-5D-5L EQ-5D 5 Level; PRO patient-reported outcome; SOB shortness of breath. Note: Participants were able to select
more than one item
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medication use for the ASD; and environmental triggers
and wheeze for the AQL-5D.
Areas of impact of asthma
Figure 3 presents the key concepts identified from the
interview sample 2 concept-elicitation data; 79 impact
areas across 15 key concepts were identified. Over 90%
of the impact areas were identified in the first nine inter-
views, providing evidence of concept saturation.
Shortness of breath was most frequently reported as
the most bothersome symptom. Nighttime symptoms
had particular significance for a number of participants;
participants described feeling more frightened, isolated,
and helpless with their nighttime symptoms. Asthma at-
tacks, particularly severe attacks, were all-consuming ex-
periences, during which participants felt frightened,
anxious, panicked, embarrassed, helpless, vulnerable,
and out of control. At such times, attention tended to
focus on symptoms, and the immediate aftermath was
associated with relief, embarrassment, and being physic-
ally drained. In between attacks, participants described
feeling worried and concerned about having another at-
tack and being alone when an attack occurred.
Activity limitations was the most significant impact
of asthma, particularly exercise and taking part in
physical activities with family and friends. Partici-
pants described periods of time when they were
unable to be (or avoided being) physically active; for
some participants, prolonged periods of inactivity
had a negative impact on their feelings of health and
well-being.
“Because I’ve been sick, I can’t exercise, I can’t lose
weight, I get fatter, and then can’t breathe and then
can’t exercise” (37-year-old female)
Participants’ ability to participate or engage socially
was affected as a result of their symptoms or through
the avoidance of triggers.
“… it is the epitome of having like friends, you not
being able to do stuff with them, and, again, it's not
like a massive chunk of my life, but it is a chunk of
my life” (33-year-old-male)
Some participants described their asthma as being part
of their everyday life; such individuals accepted their
limitations and adjusted their lives accordingly.
“It’s just one of those things. It’s frustrating, but I
have found ways around it. I mean, I will never be
able to play at that level of semi-professional sport
purely because of my respiratory endurance and
things like that, but I can still, you know, I can still
know when and where my limit is. I can still enjoy
Fig. 2 Selection of Best Questions (Interview Sample 2; n = 15). ASD Asthma Symptom Diary; EQ-5D-5L EQ-5D 5 Level; PRO patient-reported
outcome; SOB shortness of breath. Note: Participants were able to select more than one item
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exercise to a point, just not really competitive exer-
cise” (20-year-old female)
For other participants, however, the limitations of
asthma had affected their sense of achievement and feel-
ings of self-worth.
“… so wheezing makes me less able to communicate
effectively in a professional sense. It makes me feel
less willing, or less—I suppose in myself it makes
communication more difficult, because if you’re
wheezing, you’re not able to speak and express
yourself as well, so it is quite debilitating.” (41-year-
old male)
“Just deeply frustrated because I just don’t feel I can
reach my potential because of it. Whether it’s sports
or relationships or work, I just don’t feel like those
things are as fruitful as they could be” (25-year-old
female)
Table 3 provides an overview of how the key concepts
identified from the interviews related to the content of
the EQ-5D-5L.
Fig. 3 Asthma Impact Concept Map
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Discussion
The findings of this qualitative study provide evidence of
shortcomings in the EQ-5D-5L with respect to its ac-
ceptability and content validity in asthma. With the not-
able exception of the usual activities dimension, many of
the participants considered the EQ-5D-5L dimensions to
be partially or completely irrelevant, either because the
concept was not relevant to their experiences with
asthma or because the concept was not expressed in a
relevant way. Some dimensions yielded inconsistent re-
sponses due to variability in interpretations of the level
of impairment reflected in the dimension and/or because
the dimension combined multiple concepts. These issues
leave open the potential for individuals experiencing the
same level of impact to give different responses and thus
having different utility index scores, as these are derived
from the dimension scores using preference-based utility
weights. Although this could apply to any patient popu-
lation, it is especially likely in asthma where only one of
the multiple concepts in a given item is relevant, as was
the case for many of our study’s participants. In the con-
text of PRO instruments, items associated with such
problems would be strong candidates for removal from a
measure [47].
The findings in this study resonate with a qualitative
evaluation of the EQ-5D-5L in patients with diabetes
[31], in which the EQ-5D-5L items were reported as be-
ing relevant for between 24% (self-care) and 68%
Table 3 Alignment of the EQ-5D-5L Dimensions to Key Impact Concepts
Concept EQ-5D Dimension Interview Findings
Physical functioning Mobility and Usual activities ▪ Participants reported difficulties with physical functions that required
respiratory effort (e.g., climbing stairs, walking uphill, and running).
▪ EQ-5D-5L usual activities dimension was generally acceptable to
participants, and the dimension reflected the activity limitation
concepts raised in the concept-elicitation interviews.
▪ The level of mobility reflected in the EQ-5D-5L mobility dimension
(i.e., problems with walking about) was poorly aligned to the issues
experienced by most of the participants.
Self-care Self-care ▪ The EQ-5D-5L self-care item was almost universally considered to
be neither relevant nor important to the patient experience of asthma.
Emotions Anxiety or depression ▪ Participants reported a range of emotions in relation to their
asthma, e.g., frustration, low mood, worry, and embarrassment.
▪ The expression of anxiety in the EQ-5D-5L was not completely aligned
with the emotions expressed in the interviews, but the concept was seen
as more relevant than depression.
▪ The combination of depression and anxiety in one dimension was
unacceptable to some participants and led to inconsistencies in responses;
participants answered variously in terms of one or both of the issues, despite
the question and response options relating only to anxiety or depression.
▪ Participants identified emotions other than anxiety or depression as being
missing from the EQ-5D-5L.
Asthma symptoms Pain or discomfort ▪ The symptoms of asthma were central to the impact of asthma; this
impact was expressed in terms of the experiential effect (e.g., the
unpleasant and frightening experience of the symptoms themselves)
and the impact on participants’ lives (e.g., being unable to take part
in activities).
▪ Shortness of breath was described as the most bothersome symptom.
▪ Discomfort and pain were less commonly reported and were more
distal to the asthma experience; discomfort was generally more relevant
than pain.
▪ The combination of pain and discomfort in one dimension was
unacceptable to some participants and led to inconsistencies in responses;
participants answered
variously in terms of one or both of the issues, despite the question
and response options relating to pain or discomfort.
Nighttime symptoms and
sleep disturbance
Not assessed ▪ Nighttime symptoms and the associated sleep disturbance were often
reported by participants and had particular salience for some individuals.
▪ These issues were highlighted by some participants as missing from the
EQ-5D-5L.
Social functioning Not assessed ▪ For some participants, asthma had a considerable impact on their ability
to go out or engage socially.
Relationships Not assessed ▪ For individual participants, asthma impacted relationships with
friends and family, often as a result of not being able to do or take
part in certain activities.
EQ-5D-5L EQ-5D 5 Level
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(anxiety/depression) of participants. Approximately one
-half of the sample said that the overall instrument was
relevant to their experience. The authors concluded that
their findings raised questions about the content validity
of the EQ-5D for diabetes [31]. Some participants indi-
cated that while the EQ-5D-5L could be relevant to
other and possibly more severe patients, it was not rele-
vant to their own personal experience. Some patients in
our study similarly commented that the EQ-5D would
only be relevant when they were at their most severe
(e.g., during an attack); it is noted that the patients were
relatively severe in terms of asthma control and
patient-reported exacerbation history and medications.
Matza et al. [31] further noted that interviewees identi-
fied issues not captured in the EQ-5D-5L, for example,
specific activities, comorbidities, diabetes symptoms, dia-
betes treatment, emotions other than anxiety or depres-
sion, dietary issues, relationships, and social life. For the
current study, concepts reported as missing from the
EQ-5D-5L included asthma triggers, asthma symptoms,
emotions other than anxiety or depression, and sleep.
Whether or not these concepts constitute important as-
pects of HRQOL is contingent on the definition of the
concept. However, as outlined previously, there is no
agreement in the literature on the definition of HRQOL
[26, 27], and an in-depth analysis of the concept is be-
yond the scope of this paper. Nonetheless, from the pa-
tient perspective, these issues represented important
areas of impact of asthma.
It is unsurprising that the EQ-5D-5L was viewed as
less relevant than the two disease-specific instruments
used in this study. Both the ASD and AQLQ were de-
signed to focus on the issues of relevance to asthma and
were developed using considerable patient input [33,
43]. Direct patient input is now deemed fundamental
but the original EQ-5D-3L was developed at a time
when qualitative work in PRO instrument development
was neither a requirement nor commonly done. Thus,
although the EuroQol Group discussed obtaining patient
input via a survey, they decided instead to select the di-
mensions for inclusion based on a review of existing
generic health measures [42]. Nonetheless, it is essential
that the EQ-5D’s context of use is taken into account
when evaluating its quality. As a generic instrument
used for economic evaluation, the dimensions of the
EQ-5D are intended to be general, both in concept and
applicability, and would not be expected to be as prox-
imal to the disease as a disease-specific measure used to
assess outcome in clinical trials. In this respect, there is
merit in the recommendation made by the Panel on
Cost-Effectiveness in Health and Medicine in the United
States that, although the use of generic PBMs for the ref-
erence case in cost-effectiveness analyses facilitates com-
parability across studies, there is value in presenting
utility estimates obtained from other sources alongside
the reference case [48].
Regardless of the context of use, a fundamental re-
quirement for any PRO instrument is that it should not
alienate patients; that is, even if a given question does
not apply, it should still be acceptable to patients to
complete. However, a notable minority of participants in
this study expressed surprise, and at times reacted with
indignation, in relation to the EQ-5D-5L mobility and
self-care dimensions.
The 2013 NICE guideline requires sponsors to provide
qualitative, empirical evidence to show that the EQ-5D
is not appropriate for a given population [5] but neglects
to provide guidance as to what level of failure consti-
tutes ‘inappropriate,’ as noted by Matza et al. [31]. Such
lack of clarity perpetuates poor PRO measurement prac-
tice in a context in which scientific rigor is crucial. From
a regulatory standpoint, the problems with acceptability
and content validity identified in this study would be
sufficient to conclude that the EQ-5D-5L was not an ac-
ceptable PRO instrument [21]. NICE takes a different
perspective, considering a lack of content validity as
relevant only if supported by evidence that construct val-
idity and responsiveness also are adversely impacted [5].
Although studies have demonstrated variability in the
EQ-5D scores in patients with different levels of asthma
control and some other known groups [30], ceiling ef-
fects have been noted in asthma [49], and studies have
generally found the measure to be less sensitive than
asthma-specific PRO instruments [30], including the
asthma-specific preference-based AQL-5D [17, 50]. A
systematic review concluded that the EQ-5D was less
appropriate than other measures in patients with mild
disease or good disease control [30]. Much of this evi-
dence pertains to the EQ-5D-3L but the extent to which
the EQ-5D-5L overcomes these shortcomings is un-
known. However, such evidence concurs with the
present study in which participants’ comments suggest
that much of the content of the EQ-5D-5L would be
capable of demonstrating the impact of asthma only at
its most severe. Thus, the wider evidence suggests that
the EQ-5D has limitations in asthma, and especially so
in mild asthma. Under such circumstances, use of
EQ-5D in health technology assessment decision models
could undervalue the benefit of effective interventions.
The interviews were designed to explore the appropri-
ateness of the instruments to describe the impact of
asthma from the patients’ perspective. Although it was
evident that some participants made a clear distinction
between symptoms and their impact, it is likely that not
all participants differentiated their asthma experience in
this way. Thus, although some participants reported
asthma symptoms as being key omissions from the
EQ-5D-5L, this is not necessarily a threat to the
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instrument’s validity as a measure of health impact.
However, it is noted that pain is measured by the
EQ-5D-5L and is considered to be a symptom concept
[26]. As another symptom, shortness of breath, would
be equally valid but more relevant to assess in asthma
than pain. Indeed, in an exploration of the potential for
a respiratory EQ-5D “bolt-on,” shortness of breath was
identified as an appropriate candidate for an additional
dimension [51]. The bolt-on approach is in its infancy,
and different additional dimensions have varied in terms
of their impact on the EQ-5D-3L descriptive system
[52–56]. The viability of incorporating shortness of
breath into the EQ-5D, whether through a bolt-on or
some other means, would need to be explored.
There were a number of limitations associated with
this study. The convenience sampling approach meant
that asthma status was determined through self-report,
although participants presented their asthma medica-
tions at the time of interview. The sample size has impli-
cations for the generalizability of the findings to the
wider asthma population. However, a sample of 40 is
typical of qualitative studies and above that employed in
similar studies [31, 57]. In the context of cognitive
debriefing, the sample size was considered adequate to
confirm understanding and identify any problems with
the instrument items [39, 40].
It is possible that participants’ opinions of the
EQ-5D-5L could have been influenced by the other
questionnaires completed. Ordering effects were miti-
gated by varying the order in which the instruments
were completed, and there were no substantial differ-
ences between the two samples in the opinions
expressed. Knowing that they were taking part in an
asthma study may have focused participants’ attention
on asthma. However, EQ-5D data used in economic
evaluations are often collected in a disease-specific con-
text (e.g., an asthma clinical trial) and administered
alongside disease-specific instruments. It also is possible
that the participants highlighted aspects of the
EQ-5D-5L that they would not notice when completing
the measure in a clinical study. However, the other two
instruments were subject to the same focusing effects,
but did not attract the same strength of criticism.
Conclusions
The issues identified in this study raise questions regard-
ing the appropriateness of the EQ-5D-5L to assess out-
comes in asthma. Although never intended to evaluate
change before and after treatment, the EQ-5D-5L is
often used in this way and we would argue that for this
context, the EQ-5D-5 L is undoubtedly suboptimal in
asthma. For the purpose of economic evaluation in
asthma, the issues identified are sufficient to warrant
further consideration of the suitability of the EQ-5D. If
decision makers are to employ PRO measures in their
deliberations, it is crucial that the instruments used meet
at least the most basic scientific standards for acceptabil-
ity and content validity. In the current study, the
EQ-5D-5L was shown to fall short of these standards.
Further empirical research is needed to justify the appro-
priateness of the EQ-5D-5L in asthma.
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